Published in Am J Hum Genet on September 01, 1980
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
Pharmacogenomics: the promise of personalized medicine. AAPS PharmSci (2000) 2.63
Pharmacogenomic discovery using cell-based models. Pharmacol Rev (2009) 1.96
Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. Am J Hum Genet (1996) 1.73
Treatment of Neuromyelitis Optica: Review and Recommendations. Mult Scler Relat Disord (2012) 1.62
Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol (2011) 1.53
Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet (2012) 1.41
Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin (2009) 1.39
Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child (1993) 1.38
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev (2008) 1.35
Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol (2008) 1.32
Pharmacogenetics of cancer therapy: getting personal. Am J Hum Genet (1998) 1.31
Integrating pharmacokinetics knowledge into a drug ontology: as an extension to support pharmacogenomics. AMIA Annu Symp Proc (2003) 1.30
Enhanced proteolysis of thiopurine S-methyltransferase (TPMT) encoded by mutant alleles in humans (TPMT*3A, TPMT*2): mechanisms for the genetic polymorphism of TPMT activity. Proc Natl Acad Sci U S A (1997) 1.23
Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol (1995) 1.23
Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A (2005) 1.20
Pancytopenia related to azathioprine--an enzyme deficiency caused by a common genetic polymorphism: a review. J R Soc Med (1992) 1.18
Data-driven methods to discover molecular determinants of serious adverse drug events. Clin Pharmacol Ther (2009) 1.17
Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia. Br J Clin Pharmacol (2013) 1.14
Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut (2001) 1.12
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cell Mol Neurobiol (2006) 1.09
The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol (2006) 1.06
Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br J Clin Pharmacol (1999) 1.06
Relating human genetic variation to variation in drug responses. Trends Genet (2012) 1.05
The thiopurines: an update. Invest New Drugs (2005) 1.05
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Is 6-thioguanine more appropriate than 6-mercaptopurine for children with acute lymphoblastic leukaemia? Br J Cancer (1993) 1.00
Clinically relevant genetic variations in drug metabolizing enzymes. Curr Drug Metab (2011) 0.99
Phenome-wide association studies on a quantitative trait: application to TPMT enzyme activity and thiopurine therapy in pharmacogenomics. PLoS Comput Biol (2013) 0.98
Pharmacogenomics: a systems approach. Wiley Interdiscip Rev Syst Biol Med (2010) 0.97
Implementation of TPMT testing. Br J Clin Pharmacol (2014) 0.96
Improving pharmacovigilance in Europe: TPMT genotyping and phenotyping in the UK and Spain. Eur J Hum Genet (2009) 0.95
Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig Dis Sci (2004) 0.95
Is the disease course predictable in inflammatory bowel diseases? World J Gastroenterol (2010) 0.94
Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol (2010) 0.94
Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol (2001) 0.94
Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore. Eur J Clin Pharmacol (2008) 0.94
Pharmacogenomics in pediatric leukemia. Curr Opin Pediatr (2010) 0.93
Pharmacogenomics. Interview by Clare Thompson. BMJ (1999) 0.93
Pharmacogenomic progress in individualized dosing of key drugs for cancer patients. Nat Clin Pract Oncol (2009) 0.92
Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol (2004) 0.92
Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. J Crohns Colitis (2010) 0.92
Optimization of conventional therapy in patients with IBD. Nat Rev Gastroenterol Hepatol (2011) 0.92
Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest (1998) 0.91
ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut (2005) 0.91
Pharmacogenetics in inflammatory bowel disease. World J Gastroenterol (2006) 0.90
Very important pharmacogene summary: thiopurine S-methyltransferase. Pharmacogenet Genomics (2010) 0.90
Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. BMJ (2005) 0.89
Cancer pharmacogenomics. Clin Pharmacol Ther (2011) 0.89
Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol (2009) 0.88
Thiopurines in inflammatory bowel disease revisited. World J Gastroenterol (2013) 0.88
Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents. Anticancer Agents Med Chem (2010) 0.88
Comparative pharmacogenetic analysis of risk polymorphisms in Caucasian and Vietnamese children with acute lymphoblastic leukemia: prediction of therapeutic outcome? Br J Clin Pharmacol (2015) 0.87
Nucleoside salvage and resistance to antimetabolite anticancer agents. Br J Cancer (1991) 0.87
Using germline genomics to individualize pediatric cancer treatments. Clin Cancer Res (2012) 0.87
Decrease in S-adenosylmethionine synthesis by 6-mercaptopurine and methylmercaptopurine ribonucleoside in Molt F4 human malignant lymphoblasts. Biochem J (1994) 0.87
Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung (2010) 0.87
Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation. Pharmacogenet Genomics (2008) 0.87
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. Eur J Clin Pharmacol (2008) 0.86
Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics. Br J Haematol (2014) 0.86
Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci (2007) 0.86
Pharmacogenomics and adverse drug reactions in children. Front Genet (2014) 0.86
Red blood cell hypoxanthine phosphoribosyltransferase activity measured using 6-mercaptopurine as a substrate: a population study in children with acute lymphoblastic leukaemia. Br J Clin Pharmacol (1993) 0.85
Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events. J Mol Diagn (2007) 0.85
Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol (2004) 0.85
Species differences in tumour responses to cancer chemotherapy. Philos Trans R Soc Lond B Biol Sci (2015) 0.85
Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab (2009) 0.83
Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol (2012) 0.83
Therapeutic drug monitoring of immunosuppressant drugs. Br J Clin Pharmacol (1999) 0.83
Medical management of crohn disease. Clin Colon Rectal Surg (2013) 0.83
The accumulation of mercaptopurine metabolites in age fractionated red blood cells. Br J Clin Pharmacol (1995) 0.83
Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease. World J Gastroenterol (2011) 0.82
Association between thiopurine S-methyltransferase polymorphisms and thiopurine-induced adverse drug reactions in patients with inflammatory bowel disease: a meta-analysis. PLoS One (2015) 0.82
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr Neuropharmacol (2011) 0.82
TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol (2009) 0.82
The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease. Can J Gastroenterol (2013) 0.81
Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity. Drug Metab Dispos (2010) 0.81
Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes. Front Genet (2014) 0.81
Pharmacogenetics and diseases of the colon. Curr Opin Gastroenterol (2007) 0.81
Monitoring and safety of azathioprine therapy in inflammatory bowel disease. Pediatr Gastroenterol Hepatol Nutr (2013) 0.81
Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003. Br J Haematol (2015) 0.81
Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups. Br J Clin Pharmacol (2004) 0.81
Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics. J R Soc Med (1995) 0.80
Crohn's disease genotypes of patients in remission vs relapses after infliximab discontinuation. World J Gastroenterol (2012) 0.80
Pharmacogenetics of human erythrocyte thiopurine methyltransferase activity in a French population. Br J Clin Pharmacol (1991) 0.80
Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine. Int J Mol Sci (2015) 0.80
The 3'UTR NFKBIA variant is associated with extensive colitis in Hungarian IBD patients. Dig Dis Sci (2008) 0.80
Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J (2002) 0.80
Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2008) 0.80
Opportunities for translational epidemiology: the important role of observational studies to advance precision oncology. Cancer Epidemiol Biomarkers Prev (2015) 0.79
The role of pharmacogenetics in nonmalignant gastrointestinal diseases. Nat Rev Gastroenterol Hepatol (2012) 0.79
Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors. Br J Clin Pharmacol (1994) 0.79
Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can J Gastroenterol (2008) 0.79
Real-time RT-PCR methodology for quantification of thiopurine methyltransferase gene expression. Eur J Clin Pharmacol (2003) 0.79
Pretreatment determination of TPMT--state of the art in clinical practice. Eur J Clin Pharmacol (2009) 0.79
TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation. Pharmacogenet Genomics (2013) 0.79
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone. Clin Pharmacol Ther (2016) 0.79
Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis. Am J Med (1973) 4.78
Symposium on immunosuppressive drugs. Biochemistry and pharmacology of purine analogues. Fed Proc (1967) 2.44
Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med (1976) 2.33
Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet (1977) 1.94
Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.81
Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science (1979) 1.62
Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature (1974) 1.28
Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem (1963) 1.25
Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1979) 1.25
Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem Pharmacol (1969) 1.13
Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci (1978) 1.08
Therapy for acute granulocytic leukemia. Cancer Res (1967) 1.03
Human erythrocyte phenol O-methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.02
Enzymatic S-methylation of 6-n-propyl-2-thiouracil and other antithyroid drugs. Biochem Pharmacol (1975) 0.99
In vitro acetylation of drugs by human blood cells. Drug Metab Dispos (1975) 0.95
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 3.38
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther (1989) 2.51
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction. Gastroenterology (1999) 2.14
Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet (1977) 1.94
Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.81
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther (2010) 1.74
Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem (1994) 1.69
Proportional release of norepinephrine and dopamine- -hydroxylase from sympathetic nerves. Science (1971) 1.68
Phenol sulfotransferase pharmacogenetics in humans: association of common SULT1A1 alleles with TS PST phenotype. Biochem Biophys Res Commun (1997) 1.63
Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther (1987) 1.62
Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science (1979) 1.62
Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry (2004) 1.53
Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics (2000) 1.51
Human sulfotransferase SULT1C1 pharmacogenetics: gene resequencing and functional genomic studies. Pharmacogenetics (2001) 1.46
Inheritance of very low serum dopamine-beta-hydroxylase activity. Am J Hum Genet (1975) 1.40
Phenolsulphotransferase in human tissue: radiochemical enzymatic assay and biochemical properties. Clin Chim Acta (1980) 1.34
SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet (2009) 1.32
Serum dopamine beta-hydroxylase. Pharmacol Rev (1978) 1.31
Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature (1974) 1.28
Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics (1992) 1.26
Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol (1998) 1.25
Challenges in implementing genomic medicine: the Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther (2013) 1.25
Human erythrocyte thiol methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1979) 1.25
Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6-mercaptopurine and azathioprine. Br J Clin Pharmacol (1995) 1.23
Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science (1973) 1.22
Pathophysiology of postoperative ileus. Arch Surg (1977) 1.17
Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol (1999) 1.17
Pharmacogenetics of human thiopurine methyltransferase: kidney-erythrocyte correlation and immunotitration studies. J Pharmacol Exp Ther (1982) 1.17
Human liver phenol sulfotransferase: assay conditions, biochemical properties and partial purification of isozymes of the thermostable form. Biochem Pharmacol (1987) 1.16
Reduced plasma dopamine-beta-hydroxylase activity in familial dysautonomia. N Engl J Med (1971) 1.16
Human hydroxysteroid sulfotransferase SULT2B1: two enzymes encoded by a single chromosome 19 gene. Genomics (1998) 1.14
Pharmacokinetics, dose adjustments, and 6-mercaptopurine/methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency. Acta Paediatr (1998) 1.12
Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet (1982) 1.12
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut (2001) 1.11
Sulfation pharmacogenetics: SULT1A1 and SULT1A2 allele frequencies in Caucasian, Chinese and African-American subjects. Pharmacogenetics (2001) 1.11
Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther (1997) 1.10
Human liver dehydroepiandrosterone sulfotransferase: molecular cloning and expression of cDNA. Mol Pharmacol (1992) 1.10
Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet (1981) 1.09
Human erythrocyte catechol-O-methyltransferase: correlation with lung and kidney activity. Life Sci (1978) 1.08
Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol (1983) 1.07
Phenolsulphotransferase: enzyme activity and endogenous inhibitors in the human erythrocyte. J Lab Clin Med (1979) 1.06
Microassay of human erythrocyte catechol-O-methyltransferase: removal of inhibitory calcium ion with chelating resin. Clin Chim Acta (1975) 1.06
Human cytosolic sulfotransferase database mining: identification of seven novel genes and pseudogenes. Pharmacogenomics J (2004) 1.06
Elevation of serum dopamine-beta-hydroxylase activity with forced immobilization. Nat New Biol (1971) 1.05
The impact of pharmacogenomics on the management of cardiac disease. Clin Pharmacol Ther (2011) 1.05
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. J Pediatr Hematol Oncol (2000) 1.04
Human erythrocyte phenol O-methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.02
Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol (1993) 1.02
Human platelet phenol sulphotransferase: assay procedure, substrate and tissue correlations. Clin Chim Acta (1981) 1.02
Human lymphocyte thiopurine methyltransferase pharmacogenetics: effect of phenotype on 6-mercaptopurine-induced inhibition of mitogen stimulation. J Pharmacol Exp Ther (1987) 1.01
Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol (1983) 1.00
Acetaminophen and phenol: substrates for both a thermostable and a thermolabile form of human platelet phenol sulfotransferase. J Pharmacol Exp Ther (1982) 1.00
Calcium inhibition of rat liver catechol-O-methyltransferase. Biochem Pharmacol (1976) 0.99
Human intestinal phenol sulfotransferase: assay conditions, activity levels and partial purification of the thermolabile form. Drug Metab Dispos (1989) 0.99
Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics. Pharmacogenomics J (2012) 0.98
Human 3'-phosphoadenosine 5'-phosphosulfate synthetase 1 (PAPSS1) and PAPSS2: gene cloning, characterization and chromosomal localization. Biochem Biophys Res Commun (2000) 0.97
Genetic diversity and function in the human cytosolic sulfotransferases. Pharmacogenomics J (2006) 0.97
Human platelet phenol sulfotransferase: familial variation in thermal stability of the TS form. Biochem Genet (1984) 0.95
Human liver nicotinamide N-methyltransferase: ion-pairing radiochemical assay, biochemical properties and individual variation. Clin Chim Acta (1990) 0.95
Human sulfotransferase SULT1C1: cDNA cloning, tissue-specific expression, and chromosomal localization. Genomics (1997) 0.95
Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther (1991) 0.94
Human biochemical genetics of plasma dopamine-beta-hydroxylase and erythrocyte catechol-o-methyltransferase. Hum Genet Suppl (1978) 0.93
Phenol sulfotransferase in humans: properties, regulation, and function. Fed Proc (1986) 0.93
Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther (2000) 0.93
Purine substrates for human thiopurine methyltransferase. Biochem Pharmacol (1994) 0.92
Genetic polymorphism for human platelet thermostable phenol sulfotransferase (TS PST) activity. Genetics (1989) 0.92
Human sulfotransferase SULT2A1 pharmacogenetics: genotype-to-phenotype studies. Pharmacogenomics J (2002) 0.92
Human brain phenol sulfotransferase: biochemical properties and regional localization. J Neurochem (1984) 0.91
Pharmacogenetics of N-methylation: heritability of human erythrocyte histamine N-methyltransferase activity. Clin Pharmacol Ther (1988) 0.91
Sulfation of estrone and 17 beta-estradiol in human liver. Catalysis by thermostable phenol sulfotransferase and by dehydroepiandrosterone sulfotransferase. Drug Metab Dispos (1992) 0.91
Catechol-o-methyltransferase biochemical genetics: human lymphocyte enzyme. Biochem Genet (1981) 0.91
Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest (1998) 0.91
Human erythrocyte protein L-isoaspartyl methyltransferase: heritability of basal activity and genetic polymorphism for thermal stability. Arch Biochem Biophys (1997) 0.90
Human liver thermolabile phenol sulfotransferase: cDNA cloning, expression and characterization. Biochem Biophys Res Commun (1994) 0.90
Catechol-o-methyltransferase in rat erythrocyte and three other tissues: comparison of biochemical properties after removal of inhibitory calcium. J Neurochem (1976) 0.90
Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. Genomics (1995) 0.90
Inheritance of human platelet thermolabile phenol sulfotransferase (TL PST) activity. Genet Epidemiol (1988) 0.90
Sulfotransferase gene copy number variation: pharmacogenetics and function. Cytogenet Genome Res (2009) 0.89
Thiol methylation pharmacogenetics: heritability of human erythrocyte thiol methyltransferase activity. Clin Pharmacol Ther (1983) 0.89
Thiopurine methyltransferase: structure-activity relationships for benzoic acid inhibitors and thiophenol substrates. J Med Chem (1986) 0.89
Human jejunal estrogen sulfotransferase and dehydroepiandrosterone sulfotransferase: immunochemical characterization of individual variation. Drug Metab Dispos (1996) 0.89
Human sulfotransferases SULT1C1 and SULT1C2: cDNA characterization, gene cloning, and chromosomal localization. Genomics (2000) 0.88
Human liver arylamine N-sulfotransferase activity. Thermostable phenol sulfotransferase catalyzes the N-sulfation of 2-naphthylamine. Drug Metab Dispos (1992) 0.88
Aging and aldosterone. Am J Med (1983) 0.88
Human pharmacogenetics: Introduction. Fed Proc (1984) 0.88
Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics (1999) 0.87
Mouse thiopurine methyltransferase pharmacogenetics: monogenic inheritance. J Pharmacol Exp Ther (1987) 0.86
Human phenol sulfotransferase: correlation of brain and platelet activities. J Neurochem (1985) 0.86
Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics (1999) 0.85
Thiopurine methyltransferase pharmacogenetics. Cloning of human liver cDNA and a processed pseudogene on human chromosome 18q21.1. Drug Metab Dispos (1995) 0.85
Biochemical genetics of catecholamines in humans. Mayo Clin Proc (1983) 0.84
Human histamine N-methyltransferase pharmacogenetics: cloning and expression of kidney cDNA. Mol Pharmacol (1994) 0.84
Human hepatic microsomal thiol methyltransferase. Assay conditions, biochemical properties, and correlation studies. Drug Metab Dispos (1992) 0.84
Genetic segregation analysis of red blood cell (RBC) histamine N-methyltransferase (HNMT) activity. Genet Epidemiol (1993) 0.84
Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther (1980) 0.84
3'-Phosphoadenosine-5'-phosphosulfate: photoaffinity ligand for sulfotransferase enzymes. Mol Pharmacol (1991) 0.83
Human liver dehydroepiandrosterone sulfotransferase: nature and extent of individual variation. Clin Pharmacol Ther (1993) 0.83